EC17 imaging contrast agent
DrugThis is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
NCT Number: NCT01778920
The goal of this study is to perform imaging of patient's tumors while the chest is open and the tumor is being removed.
According to the World Health Organization, lung cancer is the most common cause of cancer-related death in men and women, and is responsible for 1.3 million deaths worldwide annually as of 2004. Surgery remains the best option for patients presenting with operable Stage I or II cancers, however the five year survival rate for these candidates remains at a dismal 53% for Stage I and 32% for Stage II. The high rates of recurrence suggest that surgeons are unable to completely detect and remove primary tumor nodules in a satisfactory manner as well as lingering metastases in sentinel lymph nodes. By ensuring a negative margin through imaging during surgery it would be possible for us to improve the rates of recurrence free patients and thus overall survival.
Thoracic malignancies are the ideal disease to investigate intra-operative imaging. Over 85% of lung and pleural malignancies express folate receptor alpha (FRA). It is important to note that FRA is expressed only in the proximal tubules of the kidneys, activated macrophages, and in the choroidal plexus. Thus, the false positive detection rate is expected to be extremely low. A group well known to us in the Netherlands has completed a pilot study utilizing a folate-fluorescein isothiocyanate (folate-FITC) conjugate in 12 patients with ovarian cancer. Another group of investigators in Mayo have subsequently performed this study on 20 more patients without any serious adverse events (personal communication). They report excellent sensitivity and specificity with this technique with only grade 1 side effects (allergic reaction). All side effects reversed when the injection was halted. Patients with a history of allergic reactions to insect bites should not participate (fluorescein is derived from the firefly insect, folate is an essential vitamin).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
This will identify the margins and the lymph nodes that may have cancer cells during cancer surgery
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Time frame: Within two to four hours of injection of the EC17
Measure the number of patients who have a positive margin during lung cancer surgery 2 - 4 hours after receiving administration of EC17.
Time frame: Day 1 - Day 30
University of Pennsylvania
Other
Intraoperative Imaging of Pulmonary Adenocarcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03037385
Adenocarcinoma, Adenocarcinoma, Papillary
Phoenix, Arizona, United States
View Trial DetailsNCT03535727
Adenocarcinoma, Carcinoma
Baltimore, Maryland, United States
View Trial DetailsNCT01962532
Adenocarcinoma, Carcinoma
Kashiwa, Japan
View Trial DetailsNCT01519817
Adenocarcinoma, Carcinoma
Bethesda, Maryland, United States
View Trial Details